Data from Pharmawand - Curated by EPG Health - Date added 07 June 2018
The National Institute for Health and Care Excellence has published draft guidelines rejecting the use of Zytiga (abiraterone acetate), from Janssen, plus androgen deprivation therapy and prednisone/prednisolone as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer for use in the NHS. NICE noted that the cost of the drug did not fit in with patient's treatment and added that the estimate of the effectiveness of Zytiga with ADT versus best available treatment has not been fully explored.
Zytiga is approved for use by the NHS prior to chemotherapy but only after patients have received standard hormone therapy. In 2017 European regulators approved the use of the therapy as a first-line treatment for advanced prostate cancer, alongside hormone therapy. Zytiga was tested in the multinational, Phase III LATITUDE study demonstrated a significant improvement in overall survival (OS) and significantly prolonged radiographic progression-free survival (rPFS) in patients with high-risk metastatic hormone-naïve prostate cancer (mHNPC) compared to placebo plus ADT.